Clinical Trial Update: A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and potential early efficacy of RP-A701, an AAV gene therapy, in BAG3-related dilated cardiomyopathy; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• RP-A701

Snippet

Sponsor: Rocket Pharmaceuticals Inc. | Conditions: Dilated Cardiomyopathy (DCM) | Phase 1 | Status: RECRUITING